Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Octane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 3/20 | 0.48 |
| ▸ | CES1 | P23141 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetradecane SCHEMBL23186 | 1.00 | TP53 (0.54) | TP53TSHRTHRBCA1CA2 | |
| Sulfuric Acid SCHEMBL29238027 | 1.00 | TP53 (0.54) | TP53TSHRTHRBCA1CA2 | |
| Hexadecane SCHEMBL11418243 | 1.00 | TP53 (0.54) | TP53TSHRTHRBCA1CA2 | |
| Decane SCHEMBL3962533 | 1.00 | TP53 (0.54) | TP53TSHRTHRBCA1CA2 | |
| Pentadecane SCHEMBL11413596 | 1.00 | TP53 (0.54) | TP53TSHRTHRBCA1CA2 | |
| Heptane SCHEMBL25209213 | 1.00 | TP53 (0.54) | TP53TSHRTHRBCA1CA2 | |
| Decane SCHEMBL13370386 | 1.00 | TP53 (0.54) | TP53TSHRTHRBCA1CA2 | |
| Sulfuric Acid SCHEMBL11415405 | 1.00 | TP53 (0.54) | TP53TSHRTHRBCA1CA2 | |
| Dodecane SCHEMBL21806102 | 1.00 | TP53 (0.54) | TP53TSHRTHRBCA1CA2 | |
| Dodecane SCHEMBL534861 | 1.00 | TP53 (0.54) | TP53TSHRTHRBCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105168175-A | Nisoldipine capsule and preparation method thereof | REYOUNG PHARMACEUTICAL CO LTD | 2015-12-23 | — | — | CN | claimed |
| US-20240398978-A1 | Compositions and Methods for Treating Dopamine Disorders | METAQOR LLC (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240398979-A1 | Compositions and Methods for Treating Dopamine Disorders | METAQOR LLC (US) | 2024-12-05 | — | — | US | disclosed |
| US-20220161276-A1 | MIXTURE OF FATTY ACIDS AND ALKYLETHER PHOSPHATES AS A COLLECTOR FOR PHOSPHATE ORE FLOTATION | BASF SE (DE) | 2022-05-26 | — | — | US | disclosed |
| EP-3917676-A1 | MIXTURE OF FATTY ACIDS AND ALKYLETHER PHOSPHATES AS A COLLECTOR FOR PHOSPHATE ORE FLOTATION | BASF SE (DE) | 2021-12-08 | — | — | EP | disclosed |
| US-20210353771-A1 | Compositions and Methods for Treating Dopamine Disorders | METAQOR LLC | 2021-11-18 | — | — | US | disclosed |
| CN-106604967-B | Flame-retarded heat-conducting polymer composition with good flowability characteristics and application thereof | 沙特基础工业全球技术公司 | 2019-07-16 | — | — | CN | disclosed |
| EP-3063311-B1 | CORROSION INHIBITING COMPOSITIONS AND METHODS | U S WATER SERVICES INC (US) | 2018-04-11 | — | — | EP | disclosed |
| CN-107430222-A | Reflective article including a microporous structure and having improved reflectivity | 沙特基础工业全球技术公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-107407749-A | Including microcellular structure and with the retroreflective articles of improved reflectivity | 沙特基础工业全球技术公司 | 2017-11-28 | — | — | CN | disclosed |
| US-7910024-B2 | Corrosion inhibition compositions and methods for using the same | A.S. INC. (US) | 2011-03-22 | — | — | US | disclosed |
| CN-1749867-B | Toner and image forming apparatus | CANON KK | 2010-05-05 | — | — | CN | disclosed |
| WO-2009035569-A1 | CORROSION INHIBITION COMPOSITIONS AND METHODS FOR USING THE SAME | A.S. INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090069202-A1 | Corrosion inhibition compositions and methods for using the same | A.S. INC. | 2009-03-12 | — | — | US | disclosed |
| CN-1749867-A | Toner and image forming apparatus | CANON KK (JP) | 2006-03-22 | — | — | CN | disclosed |
| CN-1655765-A | Sustained release pharmaceutical preparations and methods for producing the same | PLIVA INC (US) | 2005-08-17 | — | — | CN | disclosed |
| US-6572673-B2 | Reacting metal salts of noble metals and anionic surfactant containing an anionic group as reducing agent in water under reflux at 50-140 degree C. such that the metal salts can be reduced into uniform metal nanoparticles | CHANG CHUN PETROCHEMICAL CO., LTD. (TW) | 2003-06-03 | — | — | US | disclosed |
| US-20020194958-A1 | Process for preparing noble metal nanoparticles | CHANG CHUN PETROCHEMICAL CO., LTD. (TW) | 2002-12-26 | — | — | US | disclosed |
| CN-1385269-A | Method for producing noble metal nanoparticles | CHANGCHUN PETROCHMICAL CO LTD (CN) | 2002-12-18 | — | — | CN | disclosed |
| US-4500431-A | Separation of analysis of anions | TOYO SODA MANUFACTURING CO. LTD. (JP) | 1985-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398979-A1 | Compositions and Methods for Treating Dopamine Disorders | SLC6A3, SNCA, CLTA | TP53 3794/4885TSHR 3143/4885THRB 1678/4885 |
| US-20210353771-A1 | Compositions and Methods for Treating Dopamine Disorders | SLC6A3, SNCA, CLTA | TP53 3794/4885TSHR 3143/4885THRB 1678/4885 |
| US-20240398978-A1 | Compositions and Methods for Treating Dopamine Disorders | SLC6A3, SNCA, CLTA | TP53 3794/4885TSHR 3143/4885THRB 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.